Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) produced a 195% rally since recording the worst price of $1.20. Thanks to the latest -9% decrease, it now trades at $3.54. Throughout the trading on 11/29/2017, the share price floated between $3.52 and $4.02. This company shares are -15.25% up from its target price of $3 and the current market capitalization stands at $260.44M. The recent change has given its price a -7.29% deficit over SMA 50 and -22.03% deficit over its 52-week high. The stock witnessed -3.01% declines, 29.2% gains and 131.37% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ARWR’s volatility during a week at 6.98% and during a month it has been found around 5.86%.Arrowhead Pharmaceuticals, Inc. (ARWR) Top Holders
Institutional investors currently hold around $59 million or 20.2% in ARWR stock. Look at its top three institutional owners. Oppenheimerfunds, Inc. owns $11.67 million in Arrowhead Pharmaceuticals, Inc., which represents roughly 4.48% of the company’s market cap and approximately 19.78% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 2,892,265 shares of the stock are valued at $11.25 million. The third largest holder is Blackrock Inc., which currently holds $11.12 million worth of this stock and that ownership represents nearly 4.27% of its market capitalization.Arrowhead Pharmaceuticals, Inc. 13F Filings
At the end of 09/30/2017 reporting period, 22 institutional holders increased their position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by some 3,088,898 shares, 33 decreased positions by 3,543,042 and 16 held positions by 8,495,130. That puts total institutional holdings at 15,127,070 shares, according to SEC filings. The stock grabbed 9 new institutional investments totaling 1,653,025 shares while 14 institutional investors sold out their entire positions totaling 2,049,708 shares.Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Insider Trades
Multiple company employees have indulged in significant insider trading. Arrowhead Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Given Douglas B has sold 12,000 shares of Arrowhead Pharmaceuticals, Inc. (ARWR) in trading session dated Oct. 14, 2016. These shares are worth $80,640 and were traded at $6.72 each. The SEC filing shows that Myszkowski Kenneth Allen performed a sale of 20,000 shares. The CFO disposed these shares by way of transaction on Aug. 23, 2016. The company’s shares were given away at $8 per share worth to an income of some $160,000 on account of Myszkowski Kenneth Allen.
CFO, Myszkowski Kenneth Allen, sold 20,000 common shares of Arrowhead Pharmaceuticals, Inc. (ARWR) in the open market. In a transaction dated Aug. 23, 2016, the shares were put up for sale at an average price of $8, raking in a sum of $160,000. After this sale, 115,689 common shares of ARWR are directly owned by the insider, with total stake valued at $409,539.
In the transaction dated Dec. 30, 2015, the great number of shares disposed came courtesy the CFO; Myszkowski Kenneth Allen disposed a total of 23,347 shares at an average price of $6.13, amounting to approximately $143,117. The insider now directly owns 135,000 shares worth $477,900.Arrowhead Pharmaceuticals, Inc. (ARWR) Analyst Guide
Several analysts have released their opinion on Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), with 2 analysts believing it is a strong buy. Whereas 2 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation.